Schools get federal funding to stock naloxone and train staff for overdose emergencies

What it does

This bill amends federal law to fund grants for schools to train staff (nurses, health center workers, or designated personnel) to administer naloxone and other emergency opioid-overdose treatments on school premises. Schools must maintain accessible supplies, ensure trained staff are present during operating hours, and operate under state civil liability protections. The bill expands existing opioid-reduction grant authority to explicitly cover administration of these drugs and devices, not just prescribing.

Why we flagged it

The bill's operative mechanism is a federal grant program to equip schools with naloxone and trained personnel to administer it during overdose emergencies. This is straightforward public-health infrastructure, not a tax provision, deregulation, or private subsidy.

What the text implies

• Schools must obtain state attorney general certification that state law provides 'adequate' civil liability protection—a vague standard that may create barriers in states with weak Good Samaritan laws, effectively gatekeeping federal funding by state legal regime.
• The bill does not specify who bears the cost of naloxone supply or training; schools may face unfunded mandates if grant amounts do not cover full implementation, shifting costs to already-strained school budgets.
• Designation of 'trained personnel' is left to school principals, creating potential inconsistency in who is authorized and trained, and no federal standard for training quality or recertification.
• The bill does not address liability for schools that fail to maintain supplies or ensure trained staff presence during operating hours, creating a potential gap between certification and actual readiness.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands access to life-saving emergency overdose treatment in schools, where young people spend significant time and where overdose risk is rising. It places no new restrictions on citizens' rights or remedies; instead, it funds preparedness and protects school staff from liability when administering emergency care. The public health benefit—reducing preventable deaths among minors and young adults—outweighs any implementation costs.

Who stands to gain

• pharmaceutical manufacturers of naloxone (Ampharos Pharmaceuticals, Emergent BioSolutions, Pfizer, o
• medical device manufacturers producing naloxone delivery systems
• school-based health center operators and contractors
• training and consulting firms providing overdose-response certification

Named in the bill

U.S. Department of Health and Human Services (HHS), Public Health Service Act, Section 544 and 544A (PHS Act), State attorneys general, Elementary and secondary schools, School nurses and health center staff, Naloxone manufacturers (Ampharos, Emergent BioSolutions, Pfizer, others)

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Jun 10, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 10, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.